AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02829528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Little Flower Yoga For Kids
Description: Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
Study NCT03437096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: venipuncture pain
Description: postoperative sleeve gastrectomy patients pain
Study NCT02326532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO data utilized
Description: Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
Study NCT02326532 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PRO data not utilized
Description: Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
Study NCT04159571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the vmPFC
Description: This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
Study NCT04159571 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS to the vmPFC
Description: The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
Study NCT01688440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: #1 Respiratory Care Solution
Description: Respiratory care solution.
Study NCT00839891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VI-0521
Description: PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
Study NCT03903068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXALIN ADI AC stimulator
Description: When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
Study NCT00949910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
Study NCT02897869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: 7 doses of POL7080 alone over 2.5 days
Study NCT02897869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: 3 doses of Amikacin alone over 2.5 days
Study NCT02897869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080 + Amikacin
Description: 7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
Study NCT01752972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina
Description: 10 g/day orally for 12 weeks
Study NCT01752972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: 10 g/day orally for 12 weeks
Study NCT01277497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: Sevelamer carbonate 1,600 mg three times daily with meals
Study NCT01277497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate
Description: Calcium acetate 1,334 mg three times daily with meals for 12 weeks
Study NCT02621619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen + 0.5 mg IV hydromorphone
Description: 1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
Study NCT02621619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline + 0.5 mg IV hydromorphone
Description: 100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
Study NCT04213508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline ( 0.9% Sodium Chloride Saline)
Description: 0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
Study NCT04213508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline ( 3% Sodium Chloride Saline)
Description: 3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
Study NCT01401621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scratchoff Prompt: Name of Test
Description: A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
Study NCT01401621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scratchoff Prompt: Call to Action
Description: A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
Study NCT01401621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No scratch-off element
Study NCT02214784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neurotech Vital
Description: 12 weeks treatment for 30 minutes per day, 5 days out of 7.
Study NCT02214784 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Modified Neurotech Vital Device
Description: 12 weeks treatment for 30 minutes per day for 5 days out of 7.
Study NCT03866720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate rich breakfast
Description: A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
Study NCT03866720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein enriched breakfast
Description: A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
Study NCT02075671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid topical solution 20%
Description: Intervention used in the experimental arm only
Study NCT02075671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blu-U Light Therapy
Description: Intervention used in experimental and sham arms
Study NCT02075671 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Blu-U Light Therapy
Description: Intervention used in experimental and sham arms
Study NCT03168893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation ON
Description: Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
Study NCT03903068 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pseudo-stimulator
Description: When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
Study NCT00444912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Study NCT01906957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval training (HIIT)
Description: High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
Study NCT01906957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity continuous exercise training
Description: Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
Study NCT04000347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% benzoyl peroxide gel
Description: 2.5% benzoyl peroxide gel was given to patients for 2 weeks
Study NCT04000347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% benzoyl peroxide gel
Description: 5% benzoyl peroxide gel was given to patients for 2 weeks
Study NCT02890043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted spine surgery
Description: robot-assisted spine surgery using Tirobot system
Study NCT02890043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free-hand surgery
Description: traditional free-hand surgery
Study NCT02890043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TiRobot system
Description: a robot-assisted spine surgery system
Study NCT01928082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: 4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
Study NCT02995122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)
Study NCT02995122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT04546464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Recreation Program
Description: The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions
Study NCT02029638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume.
Study NCT02029638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 650 mg orally prior to antithymocyte globulin infusion.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: 25mg diphenhydramine orally prior to antithymocyte globulin infusion.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
Study NCT02029638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow transplant
Description: Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
Study NCT02029638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
Study NCT04457193 — intervention group
Intervention type: DEVICE
Intervention: TIF
Description: Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
Study NCT01473329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Diabetes Education
Description: The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
Study NCT00565214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
Study NCT00565214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Group 2
Description: The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
Study NCT02214485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated care
Description: Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
Study NCT02214485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lower extremity strength training
Description: Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
Study NCT01626989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP auto Advanced
Description: Auto Servo Ventilation Device
Study NCT01626989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP auto SV4
Description: Auto Servo Ventilation Device
Study NCT02075671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle only
Description: Intervention only includes the placebo vehicle solution
Study NCT03365011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide gas for inhalation
Description: Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
Study NCT03365011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gas for inhalation
Description: Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
Study NCT02978820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEAS exercise
Description: Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
Study NCT02978820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS exercise
Description: Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
Study NCT02319395 — intervention group
Intervention type: GENETIC
Intervention: Blood Sampling and DNA collection
Description: One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate.
Study NCT01064154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol Tablets 25 mg
Study NCT01064154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol Tablets 25 mg
Study NCT00222989 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PPI
Study NCT03168893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation OFF
Description: Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
Study NCT02272946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150mg Canakinumab received subcutaneously